Navigation Links
Anesiva Announces First Quarter 2008 Financial Results
Date:5/8/2008

SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported financial results and accomplishments for the first quarter ended March 31, 2008 and provided an update on its commercialization activities for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.

"This is an exciting year for Anesiva as we prepare for the commercial introduction of our first product, Zingo, in the pediatric hospital setting, while pursuing a broader label to include adults," said John P. McLaughlin, chief executive officer of Anesiva. Zingo addresses the need for rapid (one to three minutes), topical local analgesia prior to peripheral IV starts and blood draws, and is approved for use in children three to 18 years of age.

There are approximately 18 million peripheral venous access procedures in children in U.S. hospitals each year. Most currently available products are impractical to use because of their long onset of action. Yet, approximately 74% of the time children must be restrained prior to venous access procedures because of the pain associated with these procedures, a fearful experience. Anesiva believes Zingo will offer healthcare providers an important alternative to address this unmet medical need.

"We've also advanced our clinical development program for Adlea in the management of acute pain following orthopedic surgery, having initiated two Phase 3 trials since the beginning of 2008," Mr. McLaughlin said. "Top-line data from both trials are anticipated by year-end."

The most common complaint among orth
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ber 30 Biopharmaceutical company K...ts have been enrolled in its,multinational registr...esigned to show reduction in transplant related mo...ic stem cell transplantation with a mismatched,(ha...ible for an allogeneic,stem cell transplantation b...
(Date:11/30/2009)... 30 Novavax, Inc. (Nasda...ment in the Phase II clinical study of its trivale...ns) VLP vaccine candidate in healthy adults 60 yea...d, double-blind, active-controlled study is compar... two different doses (15 mcg and 60 mcg) of Novava...
(Date:11/30/2009)...0 Cell Therapeutics, Inc...t its new class of platinum-based anti-tumor compo...er anti-tumor potency and activity compared to cur...as the ability to overcome cisplatin-resistance in... a paper titled "Novel Bis-platinum Complexes Endo...
(Date:11/30/2009)...November 30 ApaTech, the rapidly g...fastest growing,Biotech/Pharmaceutical/Medical Tec...hnology Fast 500 for EMEA (Europe, Middle East and...on a companies, five-year revenue growth,for whic...period. This,achievement places ApaTech 9th overal...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4
...v. 3, 2008) When Albrecht Durer and other Renaiss...es, swabbed ink into the fine grooves and transfer...ould have guessed that centuries later the same te..., Whitehead Institute and Massachusetts Institute...ue from such "intaglio" printing to create snapsho...
...v. 3 Diplomat Specialty Pharmacy,today announced ...xecutive,management team. Dr. Patel will serve as ...he will be responsible for the management and deve...osely collaborate with the,executive team to devel...Patel will directly report to Jeff Rowe, Sr. Vice ...
...gress Toward Achievement of Milestones, CRANBURY,...) today announced financial results for the third ... accordance with U.S. Generally,Accepted Accountin...ttributable to common stockholders of $0.36 per sh...three months ended September 30, 2008. As of,Septe...
Other Biology Technology:Protein-printing technique gives snapshots of immune system defense 2Protein-printing technique gives snapshots of immune system defense 3Diplomat Specialty Pharmacy Hires Rinku A. Patel, PharmD as Director of Pharmacy Development and Operations 2Amicus Therapeutics Announces Third Quarter 2008 Financial Results 2Amicus Therapeutics Announces Third Quarter 2008 Financial Results 3Amicus Therapeutics Announces Third Quarter 2008 Financial Results 4Amicus Therapeutics Announces Third Quarter 2008 Financial Results 5Amicus Therapeutics Announces Third Quarter 2008 Financial Results 6Amicus Therapeutics Announces Third Quarter 2008 Financial Results 7Amicus Therapeutics Announces Third Quarter 2008 Financial Results 8Amicus Therapeutics Announces Third Quarter 2008 Financial Results 9Amicus Therapeutics Announces Third Quarter 2008 Financial Results 10Amicus Therapeutics Announces Third Quarter 2008 Financial Results 11
(Date:11/30/2009)...s are crucial for infection. Each binds a specific...mulates the host cell to take up the pathogen. Nor...function, for example the regulation of cell growt...been published in the current issue of the " Journ... of the sources for Listeria infections leading ...
(Date:11/30/2009)...ch is the virus,s exquisite specialisation for its...tools, like the humble lab mouse, can deliver only...riting in BioMed Central,s open access Journal of...roblem by creating a mouse that has key features o..., George Kassiotis, from the Division of Immunore...
(Date:11/30/2009)...uania, Nov. 30 Neurotechnology ( h...h-precision biometric identification technologies,...re product line: VeriLook 4.0 Software Developme...er 3.1 SDK for large-scale multi-biometric and au... Expanded capabilities in VeriLook 4.0 provide enh...
Breaking Biology News(10 mins):It takes 2 to infect 2A reductionist approach to HIV research 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 2New VeriLook 4.0 for Biometric Facial Recognition and MegaMatcher 3.1 for Multi-biometric Applications Are Now Available 3Centegra H1N1 Vaccination Clinics to Resume Tuesday Dec 1 62154 1Centegra H1N1 Vaccination Clinics to Resume Tuesday Dec 1 62154 2Centegra H1N1 Vaccination Clinics to Resume Tuesday Dec 1 62154 3Centegra H1N1 Vaccination Clinics to Resume Tuesday Dec 1 62154 4Swine Flu Tied to Rise in Pneumonias Among Young 62151 1Swine Flu Tied to Rise in Pneumonias Among Young 62151 2Swine Flu Tied to Rise in Pneumonias Among Young 62151 3Swine Flu Tied to Rise in Pneumonias Among Young 62151 4Lung Cancer Alliance Georgia Issues 4th Annual State Specific Report Card on Lung Cancer 62148 1Lung Cancer Alliance Georgia Issues 4th Annual State Specific Report Card on Lung Cancer 62148 2
... century the Czech scientist Franz Hofmeister obse...olution of proteins in egg white, some caused the ...s ranged in activity between these poles. , Hofm...) ions versus "salt-in" ions according to the magn...series" governs the strengths of ions in inducing ...
...anish . , Arlington, Virginia (May 12, 2008) I...s, have to do it. , In the Cerrado region of Braz...ent are helping researchers monitor rare and threa...er and maned wolf in and around Emas National Park...of threatened species in Brazil. , The researcher...
...E , Identifying abnormal protein levels in diabe... Researchers in Massachusetts are reporting an ad...bout the biochemical changes that occur inside the...) a leading cause of vision loss and blindness in... of ACS monthly Journal of Proteome Research, they...
Other Biology News:New clues to how proteins dissolve and crystallize 2New clues to how proteins dissolve and crystallize 3New clues to how proteins dissolve and crystallize 4Can feces save the species? 2Can feces save the species? 3American Chemical Society’s Weekly PressPac -- May 7, 2008 2American Chemical Society’s Weekly PressPac -- May 7, 2008 3American Chemical Society’s Weekly PressPac -- May 7, 2008 4American Chemical Society’s Weekly PressPac -- May 7, 2008 5American Chemical Society’s Weekly PressPac -- May 7, 2008 6American Chemical Society’s Weekly PressPac -- May 7, 2008 7American Chemical Society’s Weekly PressPac -- May 7, 2008 8
RNA Cap Analog, Trimethylated from EPICENTRE Biotechnologies
LN2 Backup, Factory Installed, All Voltages, for 3.0 and 6.7 cu ft -86C Chest Freezers & all -40C/ -86C Upright Freezers from Thermo Scientific
...bital Shakers combine high durability and performa...ramming power. The patented triple-counterbalance...g the unit to run with heavy out-of-balance loads....amination. The heavy stainless steel interior has...
...) catalyzes the transfer of the gamma-phosphate fr...randed DNA, RNA, and nucleoside 3'-monophosphates....phosphoryl polynucleotides, deoxyribonucleoside 3'...phosphates to form a 3'-hydroxyl group. Storage Bu...
Biology Products: